OLGC Orthologic (MM)

TEMPE, Ariz., Feb. 8 /PRNewswire-FirstCall/ -- OrthoLogic Corp. (NASDAQ:OLGC) announced today that management will provide an overview of the Company and its lead compound for tissue and bone healing, Chrysalin(R) (TP508), at the BIO CEO Investor Conference 2006. The presentation will be delivered at 11:30 a.m. EST on Wednesday, February 15, 2006 at The Waldorf=Astoria Hotel in New York. The presentation will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.orthologic.com/. It will be archived for 60 days. OrthoLogic is a biotechnology company focused on the development and commercialization of the novel synthetic peptide Chrysalin(R) (TP508) in two lead indications, both of which represent areas of significant unmet medical need -- fracture repair and diabetic foot ulcer healing. Based on the Company's pioneering scientific research of the natural healing cascade, OrthoLogic has become the leading company focused on tissue and bone repair. OrthoLogic is committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with equally under-served conditions. The Company maintains exclusive worldwide rights for Chrysalin. OrthoLogic's corporate headquarters are in Tempe, Arizona. For more information, please visit the Company's website: http://www.orthologic.com/. DATASOURCE: OrthoLogic Corp. CONTACT: Media, Lauren Tortorete of Biosector 2, +1-212-845-5609; or Investors, Melanie Friedman of Stern Investor Relations, +1-212-362-1200, both for OrthoLogic Corp. Web site: http://www.orthologic.com/

Copyright